Using a multistakeholder collaboratory and patient surveys to inform the conduct of personalized (N-of-1) trials.

2021 ◽  
Vol 40 (4) ◽  
pp. 230-241
Author(s):  
Lilly Derby ◽  
Ian M. Kronish ◽  
Dallas Wood ◽  
Ying Kuen K. Cheung ◽  
Elizabeth Cohn ◽  
...  
Keyword(s):  
Patient Surveys

Changes in Emergency Department Imaging: Perspectives From National Patient Surveys Over Two Decades

2017 ◽  
Vol 14 (10) ◽  
pp. 1282-1290 ◽  
Author(s):  
Andrew B. Rosenkrantz ◽  
Tarek N. Hanna ◽  
James S. Babb ◽  
Richard Duszak
Keyword(s):  
Emergency Department ◽  
Patient Surveys ◽  
National Patient

scholarly journals The increasing importance of patient surveys

1999 ◽  
Vol 8 (4) ◽  
pp. 212-212 ◽  
Author(s):  
P. D. Cleary
Keyword(s):  
Patient Surveys

scholarly journals A Literature Review of GP Knowledge and Understanding of ME/CFS: A Report from the Socioeconomics Working Group of the European Network on ME/CFS (EUROMENE)

2020 ◽  
Author(s):  
Derek Pheby ◽  
Diana Araja ◽  
Uldis Berkis ◽  
Elenka Brenna ◽  
John Cullinan ◽  
...  
Keyword(s):  
Working Group ◽  
Meta Analysis ◽  
Training Programme ◽  
Research Network ◽  
Similar Proportion ◽  
Review Of The Literature ◽  
European Network ◽  
Medline Search ◽  
Patient Surveys ◽  
Diagnostic Delays

Background and Objectives The socioeconomics working group of the European ME/CFS Research Network (EUROMENE) has conducted a review of the literature pertaining to GPs’ knowledge and understanding of ME/CFS. Materials and Methods A MEDLINE search was carried out. The papers identified were reviewed following the Synthesis Without Meta-analysis (SWiM) methodology, and were classified according to the focus of the enquiry (patients, GPs, database and medical record studies, evaluation of a training programme, and overview papers), and whether they were quantitative or qualitative in nature. Results 33 papers were identified in the MEDLINE search. The quantitative surveys of GPs demonstrated that a third to a half of all GPs did not accept ME/CFS as a genuine clinical entity and, even when they did, they lacked confidence in diagnosing or managing it. Patient surveys indicated that a similar proportion of patients was dissatisfied with the primary medical care they had received. These findings were consistent with the findings of the qualitative studies that were examined, and have changed little over several decades. Conclusions Lack of knowledge and understanding of ME/CFS among GPs is widespread, and the resultant diagnostic delays constitute a risk factor for severe and prolonged disease. Failure to diagnose ME/CFS renders problematic attempts to determine its prevalence, and hence its economic impact.

Impact of rapid infliximab infusions on access at a large academic tertiary medical center

2021 ◽  
Author(s):  
Antoinette Pusateri ◽  
Ashley Hatcher ◽  
Nisha Patel ◽  
Joy Lehman ◽  
Alice Hinton ◽  
...  
Keyword(s):  
Medical Center ◽  
Private Insurance ◽  
Clinical Information ◽  
Patient Characteristics ◽  
Infusion Time ◽  
Rheumatologic Disease ◽  
Future Directions ◽  
Patient Surveys ◽  
Inflammatory Bowel ◽  
To Receive

Abstract Purpose Infliximab promotes remission in patients with inflammatory bowel disease (IBD) and rheumatologic disease (RD). Rapid infliximab infusions (RI) reduce infusion time from 2 hours to 1 hour and can enhance access to care, as defined by capacity, safety, and patient characteristics. Our hypothesis for the study described here was that use of RI can enhance access for patients. Methods Data on all patients receiving infliximab for IBD or RD at our outpatient infusion center from February 2016 to August 2017 were retrospectively analyzed. Demographic and clinical information were collected. Results Of 348 patients who received infliximab, 205 had IBD and 143 had RD. In terms of capacity, 40% of patients received RI, resulting in a 16.1% decrease in average daily infusion time and a 9.8% increase in average daily available scheduled infusion chair time (P = 0.720). In terms of safety, 4 patients switched back to standard infusions after RI, after 3 specifically had reactions to RI. In terms of patient characteristics, more patients with RD versus IBD received RI (P = 0.020). Among the patients with RD, a lower proportion receiving RI were female (P = 0.043). For the patients with IBD, a higher proportion receiving RI were white (P = 0.048). Among both patients with RD and patients with IBD, a higher proportion receiving RI had private insurance (P = 0.016 and P = 0.018, respectively). Conclusion RI were safe and increased available chair time. Females with RD, patients of non-White race with IBD, and patients with public insurance were less likely to receive RI. Future directions include patient surveys and evaluation of implicit bias against patient factors that may impact access to RI.

Sign in / Sign up

Export Citation Format

Share Document